Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis. What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development. This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines: * Lessons to be learned from the polio experience. * Scientific advances that set the stage for new vaccines. * Factors that affect how vaccines are used in the population. * Value judgments and ethical questions raised by comparison of health needs and benefits. The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives.Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.
Kathleen R. Stratton, Jane S. Durch, and Robert S. Lawrence, Editors, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine
1 Front Matter; 2 Executive Summary; 3 Introduction; 4 Progress in Vaccine Development; 5 Considerations of Candidate Vaccines; 6 Overview of Analytic Approach and Results; 7 Review of the Analytical Model; 8 Ethical Considerations and Caveats; 9 Observations; 10 References; 11 Appendix 1: Borrelia burgdorferi; 12 Appendix 2: Chlamydia; 13 Appendix 3: Coccidioides Immitis; 14 Appendix 4: Cytomegalovirus; 15 Appendix 5: Enterotoxigenic E. coli; 16 Appendix 6: Epstein-Barr Virus; 17 Appendix 7: Helicobacter pylori; 18 Appendix 8: Hepatitis C; 19 Appendix 9: Herpes Simplex Virus; 20 Appendix 10: Histoplasma capsulatum; 21 Appendix 11: Human Paillomavirus; 22 Appendix 12: Influenza A and B; 23 Appendix 13: Insulin-Dependent Diabetes Mellitus; 24 Appendix 14: Melanoma; 25 Appendix 15: Multiple Sclerosis; 26 Appendix 16: Mycobacterium tuberculosis; 27 Appendix 17: Neisseria gonnorrhea; 28 Appendix 18: Neisseria meningitidis; 29 Appendix 19: Parainfluenza Virus; 30 Appendix 20: Respiratory Syncytial Virus; 31 Appendix 21: Rheumatoid Arthritis; 32 Appendix 22: Rotavirus; 33 Appendix 23: Shigella; 34 Appendix 24: Streptococcus, Group A; 35 Appendix 25: Streptococcus, Group B; 36 Appendix 26: Streptococcus pneumoniae; 37 Appendix 27: Information on accessing Electronic Spreadsheets; 38 Appendix 28: Summary of Workshops; 39 Appendix 29: Questions Posed to Outside Experts and List of Responders; 40 Index
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie McCormick, Padma Shetty, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Theresa Wizemann, Donna A. Alamario, Kathleen Stratton
Institute of Medicine, Board on Population Health and Public Health Practice, Committee to Review Adverse Effects of Vaccines, Ellen Wright Clayton, Erin Rusch, Andrew Ford, Kathleen Stratton
National Academy of Engineering, Institute of Medicine, Board on Global Health, Board on Population Health and Public Health Practice, Phase III Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Lonnie King, Rose Marie Martinez, Rino Rappuoli, Charles Phelps, Guruprasad Madhavan
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Alicia Gable, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Christopher B. Wilson, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Donna A. Almario, Kathleen Stratton
Institute of Medicine, Board on Health Promotion and Disease Prevention, Immunization Safety Review Committee, Marie C. McCormick, Theresa M. Wizemann, Donna A. Almario, Kathleen Stratton
Institute of Medicine, National Research Council, and Families Board on Children, Youth, and Healthy Development Committee on Adolescent Health Care Services and Models of Care for Treatment, Prevention, Leslie J. Sim, Jennifer Appleton Gootman, Robert S. Lawrence
Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee to Review the Evidence Regarding the Link Between Exposure to Agent Orange and Diabetes
National Research Council, Institute of Medicine, Board on Life Sciences, Medical Follow-up Agency, and Acquisition of Medical Countermeasures Against Biological Warfare Agents Committee on Accelerating the Research, Development, Leslie Z. Benet, Jane S. Durch, Lois M. Joellenbeck
Institute of Medicine, Medical Follow-up Agency, Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Brian L. Strom, Jane S. Durch, Lee L. Zwanziger, Lois M. Joellenbeck